Latest News

STAT Plus: Akcea, a biotech that relies on gene-blocking tech, loses its three top executives in one fell swoop

Three executives at Akcea Therapeutics (AKCA) are out less than a year after the company launched its first FDA-approved drug, Tegsedi, which is intended to treat a rare disease known as hereditary transthyretin amyloidosis, or hATTR.

Paula Soteropoulos, Sarah Boyce, and Jeff Goldberg — the chief executive officer, president and chief operating officer of the company, respectively — all left the company on Wednesday, according to a company press release issued Monday morning.

Continue to STAT Plus to read the full story…

Source link

WordPress database error: [Error writing file '/tmp/MYvLw9eS' (Errcode: 28 - No space left on device)]
SELECT SQL_CALC_FOUND_ROWS wp_posts.ID FROM wp_posts LEFT JOIN wp_term_relationships ON (wp_posts.ID = wp_term_relationships.object_id) WHERE 1=1 AND wp_posts.ID NOT IN (287237) AND ( wp_term_relationships.term_taxonomy_id IN (2) ) AND wp_posts.post_type = 'post' AND (wp_posts.post_status = 'publish') GROUP BY wp_posts.ID ORDER BY RAND() LIMIT 0, 3

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy